title: High-frequency oscillatory ventilation for acute respiratory distress syndrome in adults: a randomized, controlled trial.
abstract: Observational studies of high-frequency oscillatory ventilation in adults with the acute respiratory distress syndrome have demonstrated improvements in oxygenation. We designed a multicenter, randomized, controlled trial comparing the safety and effectiveness of high-frequency oscillatory ventilation with conventional ventilation in adults with acute respiratory distress syndrome; 148 adults with acute respiratory distress syndrome (Pa(O2)/fraction of inspired oxygen <or= 200 mm Hg on 10 or more cm H2O positive end-expiratory pressure) were randomized to high-frequency oscillatory ventilation (n = 75) or conventional ventilation (n = 73). Applied mean airway pressure was significantly higher in the high-frequency oscillation group compared with the conventional ventilation group throughout the first 72 hours (p = 0.0001). The high-frequency oscillation group showed early (less than 16 hours) improvement in Pa(O2)/fraction of inspired oxygen compared with the conventional ventilation group (p = 0.008); however, this difference did not persist beyond 24 hours. Oxygenation index decreased similarly over the first 72 hours in both groups. Thirty-day mortality was 37% in the high-frequency oscillation group and was 52% in the conventional ventilation group (p = 0.102). The percentage of patients alive without mechanical ventilation at Day 30 was 36% and 31% in the high-frequency oscillation and conventional ventilation groups, respectively (p = 0.686). There were no significant differences in hemodynamic variables, oxygenation failure, ventilation failure, barotraumas, or mucus plugging between treatment groups. We conclude that high-frequency oscillation is a safe and effective mode of ventilation for the treatment of acute respiratory distress syndrome in adults.
authors.affiliation: Pulmonary/Critical Care Medicine, Wilford Hall Medical Center, San Antonio, Texas 78236, USA. sderdak@mac.com
authors.forename: Stephen
authors.initials: S
authors.lastname: Derdak
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Mehta
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Stewart
authors.forename: Terry
authors.initials: T
authors.lastname: Smith
authors.forename: Mark
authors.initials: M
authors.lastname: Rogers
authors.forename: Timothy G
authors.initials: TG
authors.lastname: Buchman
authors.forename: Brian
authors.initials: B
authors.lastname: Carlin
authors.forename: Stuart
authors.initials: S
authors.lastname: Lowson
authors.forename: John
authors.initials: J
authors.lastname: Granton
mesh_terms: D018806:APACHE; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006439:Hemodynamics; D006612:High-Frequency Ventilation; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010100:Oxygen / Q000097:blood; D011446:Prospective Studies; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D012129:Respiratory Function Tests; D012449:Safety; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010100:Oxygen